/
Infectious Disease
Tuberculosis
82
Pipeline Programs↗
90
Active Trials↗
32
Companies Involved↗
Tuberculosis is a moderately active landscape with 82 programs across 32 companies. The most active players are BioNTech, Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.. 19 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical42
Phase 19
Phase 212
Phase 319
Approved
No programs
Analysis
Modality Breakdown
94%
Small molecule
68 of 72 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 72 classified programs, each share of the total. Modality classified for 100% of 82 pipeline programs.
Analysis
Trial Status
404
clinical trials
Completed234 · 58%
Unknown status44 · 11%
Recruiting39 · 10%
Not yet recruiting26 · 6%
Active, not recruiting22 · 5%
Terminated20 · 5%
Other19 · 5%
Clinical Trials
Trial Activity
404 trials
Paradoxical Tuberculosis Reactions in Patients Without HIV Infection
Recruiting·National Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT04052022·140 enrolled
Page 1 of 27
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)